Michael Szarek, PhD, on Research Areas of Focus for Tivozanib in RCC

March 11, 2021
Michael Szarek, PhD

The expert from SUNY Downstate Medical Center spoke about areas of research for renal cell carcinoma which he believes deserve further attention.

In an interview with CancerNetwork®, Michael Szarek, PhD, of SUNY Downstate Medical Center, highlighted areas of research within renal cell carcinoma (RCC) which he believes require further study.

Transcription:

For front-line, there’s still room for improvement. There was a study called TIVO-1 [NCT01030783], the first pivotal trial of tivozanib [Fotivda] in renal cell carcinoma, which had some results that were a bit difficult to understand. In that study, tivozanib showed a benefit to [progression-free survival], but there actually seem to be a trend against it in survival. And the sponsors came up with some reasons for why that potentially happened; there was crossover once patients progressed, and so that’s 1 plausible explanation. But I think in frontline metastatic disease, there’s still a lot of room for advancement there. It remains to be seen if tivozanib will be rechallenged in that particular line or not.